Showing results (91-100 of 4,868) with videos related to

Sort By:
Pageof 487
Urologic Oncology|August 1, 2021
How to manage patients with suspected upper tract urothelial carcinoma in the pandemic of COVID-19?Hsiang-Ying Lee, Erica On-Ting Chan, Ching-Chia Li, et al.
Urologic Oncology|August 2, 2021
The effect of tumor grade heterogeneity on recurrence in non-muscle invasive bladder cancerPatrick Ho, George W Moran, Vinson Wang, et al.
Urologic Oncology|June 11, 2021
Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN studyYoichiro Tohi, Takuma Kato, Akira Yokomizo, et al.
Urologic Oncology|July 28, 2021
The risk of death from prostate cancer in men with Gleason score 3+4 prostate cancer treated using brachytherapy with or without a short course of androgen deprivation therapyDavid D Yang, Ming-Hui Chen, Jing Wu, et al.
Urologic Oncology|July 9, 2021
Real-world burden of illness and unmet need in locally advanced or metastatic urothelial carcinoma following discontinuation of PD-1/L1 inhibitor therapy: A Medicare claims database analysisAlicia K Morgans, Zsolt Hepp, Sonali N Shah, et al.
Urologic Oncology|July 1, 2022
Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: Perioperative and early oncologic results from the MUSIC statewide collaborativeSilvia Mora, Ji Qi, Todd M Morgan, et al.
Urologic Oncology|November 21, 2022
Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysisNiranjan J Sathianathen, Henry Y C Pan, Nathan Lawrentschuk, et al.
Urologic Oncology|July 5, 2022
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitorsBenjamin Miron, Elizabeth Handorf, Kevin Zarrabi, et al.
Urologic Oncology|June 6, 2022
Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomesEarle F Burgess, J Alexa Sanders, Chad Livasy, et al.
Urologic Oncology|May 31, 2022
EDARADD silencing suppresses the proliferation and migration of bladder cancer cellsZhiwei Fang, Xiaoming Yang, Xiaosong Wei, et al.
Pageof 487